Medpace Holdings, Inc. — Q3 2022 Form 10-Q
Business context and period. Medpace is a global contract research organization providing clinical development services to pharmaceutical, biotechnology, and medical-device companies. This unaudited filing covers the three and nine months ended September 30, 2022, compared with the same 2021 periods.
Financial performance
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $383.7 million | $295.6 million | $1,065.9 million | $833.8 million |
| Operating income | $77.8 million | $53.7 million | $202.3 million | $143.8 million |
| Net income | $66.0 million | $48.6 million | $176.7 million | $131.8 million |
| Diluted EPS | $2.05 | $1.29 | $5.18 | $3.49 |
| Operating cash flow | Not provided for quarter | $251.4 million | $192.4 million |
- Q3 revenue increased 29.8%; nine-month revenue increased 27.8%. Management attributed growth principally to Oncology, Metabolic, Cardiology, and CNS services.
- Operating margin was approximately 20.3% in Q3 versus 18.2% in Q3 2021; for the nine months it was 19.0% versus 17.2%. Net margin was approximately 17.2% versus 16.4% in Q3 and 16.6% versus 15.8% year to date.
- Revenue growth outpaced operating expense growth. Direct costs rose 27.0% in Q3 and 26.2% year to date, reflecting higher reimbursed expenses and personnel costs. SG&A rose 26.3% and 21.4%, respectively, mainly from personnel costs.
- Nine-month free cash flow, calculated as operating cash flow less property and equipment expenditures, was approximately $223.7 million, versus $173.3 million in 2021.
Balance sheet, liquidity, and capital allocation
- At September 30, cash and cash equivalents were $31.0 million, down from $461.3 million at year-end 2021. Current assets were $337.7 million and current liabilities $820.9 million; advanced billings of $417.9 million were the largest current liability.
- Debt was $139.7 million, all classified as short-term and due in 2023. The company reported $110.1 million available under its $250 million revolving facility and $0.2 million of outstanding letters of credit.
- Nine-month financing cash outflow was $644.7 million, principally reflecting $800.7 million of share repurchases, partly offset by $299.2 million of revolving-credit proceeds. The company repurchased 5.46 million shares for approximately $800.5 million during the period and had completed the authorized program by quarter-end.
- Operating lease liabilities totaled $157.9 million. Property and equipment expenditures were $27.6 million for the nine months.
Changes, outlook, and risks
- Net new business awards were $470.9 million in Q3 and $1.344 billion year to date. Backlog was $2.236 billion at September 30, up 20.9% from a year earlier; approximately $1.165–$1.175 billion was expected to convert to revenue over the following 12 months. Management cautioned that awards and backlog can fluctuate and are not necessarily reliable predictors of future revenue.
- The filing provides no numerical revenue or earnings guidance. It reports approximately $2.5 billion of remaining performance obligations for active projects; this measure is distinct from reported backlog.
- Management said COVID-19 continued to affect site access, patient enrollment, and trial start-up, while the future financial impact could not be reasonably estimated. The filing also identifies inflation and pricing pressure, foreign-exchange movements, international operating risks, and the Russia-Ukraine conflict as potential risks.
- Q3 miscellaneous income included $5.6 million, primarily associated with foreign-exchange gains or losses; net interest expense was $1.6 million. The effective tax rate rose to 19.4% in Q3 and 15.5% year to date, from 11.3% and 9.7%, respectively, in 2021.
- The company added a risk factor warning that competitive or inflation-driven pricing pressure, or changes to its operating model, could reduce margins. It reported no significant changes to previously disclosed risk factors otherwise.
- Related-party dealings include clinical-services revenue from LIB Therapeutics and CinRx, as well as leases and travel services involving entities connected to the CEO. Legal proceedings and potential additional losses were described as immaterial; project-supply purchase commitments totaled $14.3 million.
Important facts for investors to verify
- Whether backlog and new awards convert to revenue at the expected pace, and how cancellations, trial delays, and foreign exchange affect conversion.
- Liquidity after the substantial repurchases: the low cash balance, $139.7 million debt balance, facility availability, and debt repayment timing.
- Whether elevated growth in personnel and reimbursed costs, inflation, or pricing competition changes operating margins.
- The continuing effects of COVID-19, international disruptions, and foreign-exchange movements on clinical programs and results.
- The terms, scale, and governance oversight of related-party revenue, leases, and other transactions.